Abcam wins another CiteAb award

Award recognises antibody company with sustained success in China

The 2018 CiteAb awards have been announced and we are thrilled to have won antibody company with sustained success in China.

One of Abcam’s core goals is to make sure that life scientists have access to the best reagents for their research. We offer a global service to our customers and deliver to over 130 countries and provide multi-lingual support. This award is testament to our commitment to help scientists advance their research globally.

We are also pleased to announce the other categories for which we were highly commended:

  • Antibody company of the year
  • Researchers’ choice
  • Antibody company succeeding in cancer biology

Dr Andrew Chalmers, Founder of CiteAb, said: “The winner for this award, Abcam, was determined based on CiteAb citation data over a five-year period from 2013–2017. The company has done extremely well over the past year in multiple markets, and has clearly seen a great deal of success. With China being such an essential region to crack, it’s great to see that Abcam has managed to do so!”

 

Alan Hirzel, CEO, said:"This Citeab award recognises our team’s dedication to serving customers and growing our business in China. We have been operating in China for more than 10 years and we are inspired by the quality and quantity of scientific discovery. We see this market as a source of innovation for the long term and we continue to invest there to anticipate and serve research needs, faster."

Sign up